| Literature DB >> 32785125 |
Dariusz Karcz1, Arkadiusz Matwijczuk2, Daniel Kamiński3, Bernadette Creaven4, Ewa Ciszkowicz5, Katarzyna Lecka-Szlachta5, Karolina Starzak1.
Abstract
Classical synthetic protocols were applied for tEntities:
Keywords: 1,3,4-thiadiazole; antibacterial; antioxidant; kanamycin; neurodegeneration; synergistic effect; thiadiazole complex; thiadiazole ligands
Mesh:
Substances:
Year: 2020 PMID: 32785125 PMCID: PMC7461131 DOI: 10.3390/ijms21165735
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Structures of the 1,3,4-thiadiazole-derived ligands 1, 2, 3, and the numbering system of atoms (red) used for the assignment of the 1H and 13C NMR chemical shifts.
Figure 2Synthetic pathway for the synthesis of 1,3,4-thiadiazole-derived ligands 1–3, and their corresponding Cu(II) and Zn(II) complexes 4–7: (A) POCl3, 75 °C; (B) Ac2O, H2O, reflux; (C) Ac2O, H2SO4, reflux; (D) Cu(CH3COO)2xH2O, MeOH/H2O, reflux; (E) Zn(CH3COO)2xH2O, MeOH/H2O, reflux. For better clarity, the hydrated water was omitted in the structures of complexes.
1H-NMR signals of the 1,3,4-thiadiazole derivatives 1–3.
| Thiadiazole Serivative | 1H-NMR Signals: δ (ppm) *, Multiplicity **, and J Value (Hz) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| H7 | H8 | H9 | H10 | H11 | H12 | H14 | H16 | H18 | |
|
| 10.91, | 6.38, | 9.84, | 6.36, | 7.53, | 7.15, | - | - | - |
|
| 10.90, | 6.45, | 9.92, | 6.40, | 7.91, | 12.32, | 2.18, | - | - |
|
| - | 7.29, | - | 7.26, | 8.2, | 12.68, | 2.22, | 2.31, | 2.38, |
* = numbering system of atoms shown in Figure 1; ** s = singlet, d = doublet, dd = double doublet.
Figure 3Crystal structure of thiadiazole 1. (A) Atoms are numbered according to the cif file (see supplementary material); (B) Packing of the molecules in a crystal net (for better clarity, the hydrogen atoms are omitted).
13C-NMR data of the 1,3,4-thiadiazole derivatives 1–3.
| Thiadiazole Derivative | 13C-NMR Signals (ppm) * | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C2 | C5 | C6 | C7 | C8 | C9 | C10 | C11 | C13 | C14 | C15 | C16 | C17 | C18 | |
|
| 167.84 | 156.03 | 108.98 | 156.43 | 103.00 | 160.22 | 108.35 | 129.20 | - | - | - | - | - | - |
|
| 168.79 | 158.87 | 109.15 | 156.35 | 102.88 | 160.94 | 108.62 | 129.03 | 158.89 | 22.88 | - | - | - | - |
|
| 169.24 | 155.92 | 121.36 | 147.89 | 118.21 | 152.53 | 121.02 | 129.72 | 160.03 | 22.87 | 168.96 | 21.31 | 169.33 | 21.68 |
* = numbering system shown in Figure 1.
Crystallographic parameters and details of refinement for the measured crystal of compound 1. The labels are related to the Figure 3A.
| Parameter | Value |
|---|---|
| Molecular formula | C8H7N3O3S |
| Temperature (K) | 120(2) |
| Crystal system | monoclinic |
| Space group | I 2/a |
| 13.421(2) | |
| 7.1590(10) | |
| 18.454(2) | |
| 90 | |
| 100.79(2) | |
| 90 | |
| 1741.73 | |
|
| 8 |
| Calculated density (g cm−3) | 1.596 |
| Absorption coefficient (mm−1) | 3.133 |
| 864 | |
| Completeness | 97% |
| θ range for data collection (°) | 4.88–76.15 |
| Index ranges | −13 ≤ h ≤ 16 |
| Reflections collected/unique | 6137/3789 |
| Observed/restraints/parameters | 1761/0/151 |
| Goodness-of-fit on | 1.217 |
| Final R indices (I > 2 sigma(I)) | R1 = 0.0551 |
| R indices (all data) | R1 = 0.0709 |
| Largest diff. peak and hole (e Å−3) | 0.5/−0.7 |
| CCDC number | 1845297 |
Figure 4Mass spectra of thiadiazole derivatives 1, 2, and 3 (A, B, and C, respectively) together with their respective mass chromatograms (insets).
Microanalysis (C,H,N), AAS, molecular weight, and chemical formulae of thiadiazole derivatives 1–7.
| Compound No | %C | %H | %N | %M * | Mw ** (g/mol) | Chemical Formula ** | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Calc | Found | Calc | Found | Calc | Found | Calc | Found | |||
|
| 45.93 | 42.96 | 3.37 | 3.30 | 20.08 | 17.84 | - | - | 209.22 | C8H7N3O2S |
|
| 47.80 | 46.34 | 3.61 | 3.41 | 16.72 | 16.21 | - | - | 251.26 | C10H9N3O3S |
|
| 50.15 | 49.02 | 3.91 | 3.66 | 12.53 | 12.50 | - | - | 335.33 | C14H13N3O5S |
|
| 37.24 | 26.85 | 3.13 | 2.34 | 16.29 | 10.69 | 12.31 | 24.67 | 516.01 | C16H16CuN6O6S2 |
|
| 32.58 | 30.98 | 3.55 | 2.74 | 11.40 | 12.02 | 17.73 | 16.93 | 368.67 | C10H13N3O6SZn |
|
| 40.03 | 37.67 | 3.36 | 2.95 | 14.01 | 12.90 | 10.59 | 12.04 | 600.08 | C20H20CuN6O8S2 |
|
| 35.09 | 37.01 | 3.68 | 3.02 | 10.23 | 11.55 | 15.92 | 13.21 | 470.71 | C12H15N3O7SZn |
* M = Metal. ** Proposed based on CHN and AAS analysis.
Antioxidant activity and IC50 values of free thiadiazole ligands 1–3 and TROLOX after 30 minutes of reaction with DPPH· radicals (± standard deviation (SD) calculated from experiments carried out in triplicate).
| Compound | mM Antioxidants/mM TE | IC50 (mM) | ||
|---|---|---|---|---|
|
| 0.08 | ±0.00 | 0.60 | ±0.01 |
|
| 0.35 | ±0.03 | 0.13 | ±0.00 |
|
| 0.41 × 10−3 | ±0.02 × 10−3 | 126.78 | ±2.25 |
|
| 1.00 | ±0.01 | 0.05 | ±0.00 |
MIC values of thiadiazole derivatives against S. aureus, E. coli, and p. aeruginosa referenced to commercially used antibiotics.
| Compound Bacteria | MIC (μg/mL) (±0.01) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 5 | 7 | Ampicillin | Tetracycline | Erythromycin | Kanamycin | |
|
| 500 | - | - | 500 | 500 | 1.9 | 0.1 | 250 | 3.9 |
|
| 1000 | - | - | 1000 | 1000 | 31.2 | 0.5 | 62.5 | 7.8 |
|
| - | - | - | - | - | 62.5 | 500 | 250 | - |
Synergistic effects against S. aureus demonstrated by 1 and 5 upon their combination with kanamycin.
| Compound | MIC a (µg/mL) (±0.01) | Combination | MIC b (µg/mL) (±0.01) | FIC c |
|---|---|---|---|---|
|
| 500 | 125 | 0.375 | |
| kanamycin | 3.9 | 0.5 | ||
|
| 500 | 125 | 0.375 | |
| kanamycin | 3.9 | 0.5 |
a MIC = value determined in an individual compound (1, 5, and kanamycin); b MIC = value determined in a combination of two compounds (1 or 5 with kanamycin); c FIC = fractional inhibitory concentration [40].